Studies point in different directions · confidence 70% · Atlas ID H3
The gap
mTORC1 is needed to build muscle, yet turning it down is also the best-known way to extend lifespan — a real tension. In one mouse study, giving rapamycin only temporarily (not continuously) extended how long males lived by 60%, but did nothing for females, and actually caused more aggressive blood cancers in females. So “give it in pulses, not continuously” isn't a simple fix — it may work differently by sex.
Technical framing: mTORC1 is required for muscle (raptor-KO dystrophy; DRU2009 blocks human MPS; ROM2001 hypertrophy) yet mTOR inhibition is the leading longevity lever. QUANTIFIED: BIT2016 transient rapamycin (8 mg/kg i.p. x 90 days) -> males +60% post-treatment life expectancy (p=0.02), but females NO survival benefit (p=0.26) and MORE aggressive hematopoietic cancers (16/16 vs 6/12 controls, p=0.002). So 'transient dosing captures the benefit' holds, but sex-specifically and with a female harm signal a pulsed/muscle-sparing design must control for.
The hypothesis
Educated guess: giving mTOR-blocking drugs in short pulses — timed so the drug clears the body right after exercise — might preserve muscle while still giving most of the longevity benefit.
Technical framing: Time-restricted / pulsed mTORC1 inhibition (drug trough permitting post-exercise anabolic windows) preserves muscle mass while still capturing the longevity benefit.
How it could be tested
Mouse: continuous vs pulsed rapamycin timed around resistance loading; endpoints lifespan + muscle mass/fiber CSA + autophagic flux (LC3-II/p62). Prediction: pulsed arm preserves muscle at similar healthspan.
